PAQ Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 Summit Dr Ste 916, Burlington, Massa...Website
www.paqtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About PAQ Therapeutics
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. With the company's ATTEC (autophagosome-tethering compound) technology, the company is developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway. PAQ's research advances are driving an important new class of degradation therapies with the potential to fundamentally transform drug discovery and development and target a range of substrates including proteins, aggregates, lipids, organelles and pathogens.Explore more
PAQ Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PAQ Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if PAQ Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at PAQ Therapeutics
Website visits: Recent activity has been detected on your website
Click to see if PAQ Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
PAQ Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if PAQ Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once PAQ Therapeutics has new funding data
Product Launch: Get notified when PAQ Therapeutics launches new products
Earning: See what the market has to say on PAQ Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at PAQ Therapeutics
Find more new buyers
Compare Similar Companies to PAQ Therapeutics
Compare insights from companies similar to PAQ Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PAQ Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PAQ Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PAQ Therapeutics.
PAQ Therapeutics financials insights
Gather financial insights about PAQ Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$30M
2025
Series B
$39M
PAQ Therapeutics Tech Stack
A closer look at the technologies used by PAQ Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
Person-Based
Person-Based
PAQ Therapeutics News & Media
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
BURLINGTON, Mass., Jan. 22, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader. The Series B extension builds on PAQ's previously announced Series B financing, withPAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need
--Series B co-led by MRL Ventures Fund (MRLV) and Bayland Capital, with participation from Johnson & Johnson Innovation – JJDC Inc., LAV Fund, BioTrack Capital, and Sherpa Health Partners-- --First patient dosed in Phase 1 clinical study of lead candidate PT0253, a potent, selective KRAS...PAQ Therapeutics Appoints Andrew Krivoshik, MD, PhD, as Chief Medical Officer, Announces Addition of Eric Rubin, MD, and Piro Lito MD, PhD, to Advisory Board
--Expansion of leadership to facilitate robust clinical development strategy, progress company pipeline of potent and selective KRAS degraders-- BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding PAQ Therapeutics
Sign Up For FreeTo access detailed company insights
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. With the company's ATTEC (autophagosome-tethering compound) technology, the company is developing a novel class of small molecule degraders capable of bi... Read More
